RGNX and Novartis just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA). (SMA)Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe. It is the number one genetic cause of death for infants. According to a company filling, price tag for...
I would take SL as 45.5 if you go big or SL as 42 if you can bear the loss on small size.
Some potential profit targets and short entries listed above. Short targets listed below.
This stock has been following a channel up pattern and it seems very steady. I would buy at the intersection between the 14,48 fibonacci retracement level and the trendline i drew on the chart.